-The Business Standard Interview with Founder chairman of Cancer Patients Aid Association Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting. Sapru, founder chairman of Cancer Patients Aid Association, or CPAA (which moved the Supreme Court to keep the prices of the cancer drug low), tells Sushmi Dey what the judgment means to cancer patients....
More »SEARCH RESULT
Total Matching Records found : 759
Delhi lacks basic services: CAG report-Devjyot Ghoshal and Ruchika Chitravanshi
-The Business Standard CAG state audit report NCT has also unearthed a glaring lack of planning cutting across projects, sectors It may be India's capital city, but behind the New Delhi's storied corridors of power and flush coffers, the metropolis is a difficult mess for the ordinary citizen. The Comptroller and Auditor General's (CAG) state audit report for the National Capital Territory (NCT) of Delhi government has unearthed a series of significant shortcoming...
More »Supreme Court rules for cheap cancer drug -Subodh Varma
-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...
More »SC’s Glivec ruling setback to foreign pharma firms -Vidya Krishnan and CH Unnikrishnan
-Live Mint SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness In a landmark judgement, India's apex court rejected Swiss drug maker Novartis AG's legal challenge aimed at securing a patent for blockbuster anti-cancer drug imatinib mesylate, branded Glivec in the country. The verdict, which is seen as a setback to multinational pharmaceutical companies operating in India, may influence a rash of pending disputes...
More »Novartis loses patent battle in SC
-The Business Standard Court denies Swiss drug firm patent protection for its anti-cancer drug Glivec; domestic industry hails verdict The Supreme Court on Monday dismissed Novartis AG's appeal for patent protection of its anti-cancer drug, Glivec, putting an end to a seven-year battle between the Swiss drug maker, several domestic generic manufacturers, as well as patient groups fighting for affordable medicines. A Bench of judges Aftab Alam and Ranjana Desai said in a...
More »
